Genzyme Announces Multi-Year Multiple Sclerosis Research Collaboration with Leading Academic Medical Center

This innovative collaboration aligns the research efforts of both organizations around projects which are designed to develop a deep understanding of the pathogenesis and progression of MS and to address the unmet medical needs in MS, particularly progressive forms of the disease. Initially the collaboration will focus on projects that explore strategies to address neurodegeneration, a hallmark of progressive MS, and novel technologies to better understand the pathology of the disease. The collaboration will be led by a joint steering committee comprised of Genzyme and Cleveland Clinic researchers and span a minimum of 5 years.

As leaders in MS we want to advance and build a sustainable pipeline of novel therapeutic approaches, and our collaboration with Cleveland Clinic, along with our internal R&D efforts, reinforce Genzymes long-term commitment to the MS community, said David Meeker, President and CEO, Genzyme. We are excited to work collaboratively with a premier research and health care institution that has made many important contributions to better understanding this complex and devastating disease.

Cleveland Clinics Mellen Center for Multiple Sclerosis has one of the largest and most comprehensive programs for MS care and research worldwide, managing more than 20,000 patient visits everyyear. The Center has a highly innovative and active research team, which has been at the forefront of MS advances for the past two decades.

This collaboration will allow for the development of innovative approaches to evaluate potential new therapies for progressive MS, said Dr. Jeffrey Cohen, M.D., Director of the Experimental Therapeutics Program at the Mellen Center for Multiple Sclerosis.

More than 2.3 million people worldwide have been diagnosed with MS, including approximately 400,000 people in the United States.

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzymes portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the worlds largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at http://www.genzyme.com.

Genzymeis a registered trademark.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Read the rest here:
Genzyme Announces Multi-Year Multiple Sclerosis Research Collaboration with Leading Academic Medical Center